Mostafa Faisal, Adjunct Assistant Professor at Alfaisal University, shared a post on X:
“Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland.
Brexu-cel in r/r MCL (Germany & Switzerland)
- 113 patients, heavily pretreated; 23% ZUMA-2–ineligible
- Responses (n=85): CR 61%, PR 27%; median DOR 31 mo
- Outcomes: median EFS 25 mo, OS 41 mo (≈ ZUMA-2)
- Risk: POD12 = only independent predictor of worse EFS/OS
- Infections in 31%; NRM 13% at 1 yr
- Prolonged B/T-cell suppression; IVIG → numerically better survival
- Post-CAR-T failure: very poor prognosis (median OS 4.8 mo)
- Take-home: brexu-cel effective in routine care, but early NRM + post-CAR-T relapse remain key challenges.”
Title: Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland
Authors: Linda Simon, Vladan Vucinic, Kai Rejeski, Maria-Luisa Schubert, Enver Aydilek, Eva-Maria Wagner-Drouet, Olaf Penack, Malte von Bonin, Bastian von Tresckow, Marcel Teichert, Reinhard Marks, Christiane Pott, Martin Fehr, Corinna Leng, Roland Schroers, Christian Koenecke, Johannes Duell, Stephan Stilgenbauer, Fabian Mueller, Judith S. Hecker, Uta Brunnberg, Nicolaus Kroeger, Kai Kronfeld, Matthias Theobald, Peter Dreger
Read the Full Article.
More posts featuring Mostafa Faisal on OncoDaily.